Jian Liu

Dr. Jian Liu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
HCHuixin Cheng
Huixin Cheng
XWXuehan Wang
Xuehan Wang
JYJuyi Yao
Juyi Yao
CYChunbo Yang
Chunbo Yang
JLJian Liu
Jian Liu
Sepsis is a common critical illness characterized by high mortality rates and a significant disease burden. In the context of sepsis-induced organ dysfunction, the lungs are among the initial organs affected, which may progress to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Recent studies have highlighted the crucial roles of mitophagy and ferroptosis in the development and progression of sepsis-induced ALI/ARDS. Identifying key convergence points in these processes may provide valuable insights for the treatment of this condition. In recent years, certain herbs and their bioactive compounds have demonstrated unique benefits in managing sepsis-induced ALI/ARDS by modulating mitophagy or ferroptosis. This review summary the mechanisms of mitophagy and ferroptosis, explores their interactions, and emphasizes their regulatory roles in the progression of sepsis-induced ALI/ARDS. Additionally, it offers a novel perspective on treatment strategies by summarizing various herbs and their bioactive compounds relevant to this condition.

1 September 2025 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
YXYunpeng Xu
Yunpeng Xu
LZLei Zhang
Lei Zhang
LZLei Zhu
Lei Zhu
ZYZi Yang
Zi Yang
XBXue Bai
Xue Bai
JLJian Liu
Jian Liu
Chronic Obstructive Pulmonary Disease (COPD) is a prevalent chronic respiratory disorder characterized by airway inflammation and irreversible airflow limitation. Its marked heterogeneity and complexity pose significant challenges to traditional clinical assessments in terms of prognostic prediction and personalized management. In recent years, the exploration of biomarkers has opened new avenues for the precise evaluation of COPD, particularly through multi-biomarker prediction models and integrative multimodal data strategies, which have substantially improved the accuracy and reliability of prognostic assessments. This review summarizes the key biomarkers associated with COPD prognosis, systematically discusses the practical applications and future potential of combined predictive models and multimodal data integration, and evaluates their translational value in clinical practice. As a narrative review, this study aims to provide a scientific foundation for the precision management of patients with COPD.

5 February 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Open access
YXYunpeng Xu
Yunpeng Xu
LZLei Zhang
Lei Zhang
CCChen Chen
Chen Chen
MZMingyang Zou
Mingyang Zou
KWKe Wang
Ke Wang
JLJian Liu
Jian Liu
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death globally, significantly burdening healthcare and economies. Studies show Yupingfeng (YPF) combined with conventional treatments (CT) can effectively control COPD progression, improving lung function and quality of life. This study aims to comprehensively explore the multiple therapeutic effects and potential pharmacological mechanisms of YPF in the treatment of COPD through various approaches, including meta-analysis, network pharmacology, molecular docking, and molecular dynamics simulations. We searched PubMed, Embase, Cochrane Library, Web of Science, CNKI, Wanfang Data, VIP, and CBM databases up to June 2024. Meta-analysis was conducted using Review Manager 5.4 and Stata 16.0. The certainty of evidence was assessed using the GRADE system. Network pharmacology, molecular docking, and dynamics simulations were employed to explore mechanisms and evaluate the binding of YPF's active components to targets. The meta-analysis showed that YPF combined with CT significantly improved COPD treatment efficacy compared to CT alone (moderate certainty). Lung function markers, including FEV1% pred (high certainty), FVC (moderate certainty), and FEV1/FVC (high certainty), also improved significantly. Secondary outcomes, such as Traditional Chinese Medicine (TCM) syndrome scores, CAT scores, and inflammatory and immune biomarkers, also showed improvement (low certainty). Network pharmacology identified potential YPF targets, including ESR1, SRC, EP300 and HSP90AA1, possibly involving calcium and cAMP signaling pathways. Molecular docking and dynamics simulations suggested that YPF may exert its effects by stabilizing the binding of isorhamnetin to HSP90AA1. This study demonstrates that YPF combined with CT can enhance the treatment efficacy for COPD, improving lung function and quality of life, with strong anti-inflammatory and immunomodulatory effects, and good safety. The molecular docking and molecular dynamics simulation results suggest that isoflavanone, isorhamnetin, and Atracylentriol may be the active components with strong binding affinity for COPD treatment, with HSP90AA1_isoflavanone showing the best performance in terms of stability and binding energy, second only to the standard ligand, and possibly being one of the key mechanisms of YPF in treating COPD.

1 September 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
LGLi-Na Gao
Li-Na Gao
DYDong Yan
Dong Yan
XLXiao-Hui Liu
Xiao-Hui Liu
DCDe Chen
De Chen
HGHong Guo
Hong Guo
JLJian Liu
Jian Liu
Background: Approximately 7– 13% of pregnant women with preeclampsia (PE) develop acute kidney injury (AKI), which is one of the most serious complications of PE and is linked to long-term chronic kidney disease. This retrospective observational study investigated the association between inflammation indices and PE-related acute kidney injury (PE-AKI). Methods: This retrospective study analyzed 4071 PE patients admitted between 2013 and 2023. Inflammatory indices, including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI), were derived from complete blood counts. Multivariate logistic regression assessed associations with PE-AKI risk, with nonlinear relationships characterized using restricted cubic spline models. Results: Among 4071 patients with PE, 290 (7.13%) developed AKI. Multivariate analysis (Model 3) revealed significant positive associations between log2-transformed inflammatory indices and PE-AKI risk, with the highest odds ratios observed for MLR (OR = 6.02, 95% CI: 4.68– 7.73; P < 0.0001) and NLR (OR = 3.93, 95% CI: 3.09– 5.01; P < 0.0001). MLR demonstrated the strongest independent correlation with PE-AKI (highest tertile OR = 7.24, 95% CI: 4.75– 11.02), followed by SIRI (OR = 5.78, 95% CI: 3.89– 8.59). All indices (NLR, MLR, PLR, SII, SIRI) exhibited linear dose-response relationships with PE-AKI risk (P-overall < 0.001 for each). Subgroup analyses further identified elevated MLR as a prominent risk factor in early-onset PE (gestational age ≤ 32 weeks; OR = 8.81, 95% CI: 4.91– 17.10) and patients with complications (OR = 7.28, 95% CI: 5.23– 10.32). Conclusion: MLR and SIRI are positively associated with PE-AKI risk, particularly in early-onset and complicated cases. This first comprehensive assessment of five biomarkers supports clinical utility. Prospective validation is required, with focus on monocyte-mediated inflammatory mechanisms.

1 July 2024 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
MCMingming Chen
Mingming Chen
SCShuting Chang
Shuting Chang
YXYunpeng Xu
Yunpeng Xu
HGHong Guo
Hong Guo
JLJian Liu
Jian Liu
Chronic Obstructive Pulmonary Disease (COPD) exerts a severe toll on human health and the economy, with high prevalence and mortality rates. The search for bioactive components effective in the treatment of COPD has become a focal point of research. Beetroot juice, readily accessible and cost-effective, is noted for its ability to enhance athletic performance and for its preventive and therapeutic impact on hypertension. Beetroot juice is a rich source of dietary nitrates and modulates physiological processes via the nitrate-nitrite- nitric oxide pathway, exerting multiple beneficial effects such as antihypertensive, bronchodilatory, anti-inflammatory, antioxidant, hypoglycemic, and lipid-lowering actions. This paper provides a review of the existing research on the effects of beetroot juice on COPD, summarizing its potential in enhancing exercise capacity, lowering blood pressure, improving vascular function, and ameliorating sleep quality among patients with COPD. The review serves as a reference for the prospective use of beetroot juice in the symptomatic improvement of COPD, as well as in the prevention of exacerbations and associated comorbidities.

24 March 2025 in Inflammation
Verified
Journal Article
Open access
PDF file
DCDe Chen
De Chen
XLXuan Liang
Xuan Liang
LZLei Zhang
Lei Zhang
JZJingjing Zhang
Jingjing Zhang
LGLina Gao
Lina Gao
JLJian Liu
Jian Liu
Sepsis-induced cardiomyopathy (SIC) is a severe complication of sepsis. Therefore, understanding SIC pathogenesis and developing new therapeutic targets are of great significance. This study investigated the role of F-box-only protein 32 (FBXO32) in SIC pathogenesis. LPS-induced cardiac injury models were established in rats and H9c2 cells using lipopolysaccharide. The effects of FBXO32 on myocardial apoptosis and mitochondrial structure and function were determined using electron microscopy, reactive oxygen species detection, and JC-1 staining. The molecular mechanism was elucidated using western blotting and co-immunoprecipitation. The results showed elevated FBXO32 expression in both in vivo and in vitro LPS-induced cardiac injury models. Fbxo32 knockdown alleviated apoptosis and mitochondrial and cardiac dysfunction. Mechanistic analysis revealed that FBXO32 promoted ubiquitination and degradation of annexin A1 (ANXA1), inhibiting the phosphatidylinositol 3-kinase (PI3K) and protein kinase B (AKT) pathways. Rescue experiments demonstrated that Anxa1 knockdown reversed the effects of Fbxo32 knockdown. This study suggests that FBXO32 exacerbates LPS-induced cardiac injury progression by mediating ANXA1 ubiquitination and inhibiting the PI3K/AKT signaling pathway.